Fatty Liver Disease

Fatty liver disease is fundamentally an ATP deficiency specific to the liver, a state of energetic failure in which the organ lacks the energy to process and export fat. 2 Dinkov has emphasized that the condition is not a primary disease but a suboptimal adaptation: the body sequesters fat in the liver to protect other organs from the more immediate lethal threat of diabetic ketoacidosis or circulating free fatty acids. 2 The fat accumulation originates from only two sources—excessive lipolysis releasing free fatty acids from adipose tissue, or excessive dietary fat intake—and the liver’s inability to oxidize or export this influx. 2

The nature of the stored fat determines the pathology. Dinkov argues that it is specifically polyunsaturated fats (PUFA) that cause hepatocyte swelling and inflammatory damage, while a fatty liver composed of saturated fats can remain perfectly healthy and will eventually be oxidized or excreted. 9 Peat confirmed that PUFA is probably essential for the atherogenic and steatotic process, accumulating quickly with overfeeding. 3 The peroxidative attack on stored PUFA generates the reactive oxygen species responsible for most liver damage, making the condition an inflammatory disorder synergized by estrogen. 2 Dinkov notes that anti-estrogenic substances—progesterone, DHT, aromatase inhibitors, and aspirin—have been shown to rapidly reverse NAFLD, NASH, and even cirrhosis. 9 Chronically elevated cortisol is another direct driver, triggering both lipolysis and the activation of the enzyme fatty acid synthase to synthesize new triglycerides for hepatic storage, even when cortisol levels remain within the conventional normal range. 10

Therapeutic interventions target the energetic deficit and the suppression of lipolysis. Dinkov reports that intravenous administration of ATP precursors like inosine or adenosine made fatty liver “magically disappear within days,” confirming the centrality of energy metabolism. 2 Niacinamide (vitamin B3) addresses this by elevating the NAD+/NADH ratio, which increases ATP levels, restrains excessive lipolysis, and accelerates glucuronidation detoxification up to 40-fold. 3 Dinkov has written that niacinamide also inhibits the pathogenic microRNA miR-93, thereby derepressing the NAD+-dependent deacetylase SIRT1, a dual mechanism for resolving steatosis. 5 A single low dose of 100 mg niacinamide has been observed to drop triglyceride levels by 75% in humans, and Dinkov recommends 300–500 mg daily to keep lipolysis in check. 2 Vitamin E (800 IU alpha-tocopherol daily) has been demonstrated to reverse well-established NASH in approximately six months, even in patients with highly compromised liver function such as those with HIV. 2

The condition is dissociated from body weight. Dinkov and Roddy have discussed that some of the worst cases of NAFLD are found in very lean individuals, because a skinny person with impaired mitochondrial respiration cannot muster the energy-requiring de novo lipogenesis response that safely sequesters electrons into new fat. 2 Instead, free fatty acids circulate and damage the liver, causing a catabolic state. 11 Roddy has linked this hepatic impairment to hair loss, proposing a pathway where liver dysfunction decreases SHBG, increasing free testosterone and consequently DHT. 4 Peat recommended sucrose over pure starch or isolated fructose, noting that with a good liver a person can store substantial glycogen, and that intermittent sugar consumption offers no advantage. 2 Dinkov adds that acute fasting may temporarily improve mitochondrial function, but prolonged fasting exacerbates the problem by driving lipolysis. 6